

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On September 8, 2005

TOWNSEND and TOWNSEND and CREW LLP

By:

Aaron Hokamura



PATENT
Attorney Docket No.: 021956-000500US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rajiv PARIKH et al.

Application No.: 10/659,408

Filed: September 10, 2003

For: METHOD FOR TREATING
AIRWAY DISORDERS

Examiner:

Art Unit:

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.


Also enclosed is a letter from the party citing these documents. Please note that the "Exhibit A" indicated in the letter is not enclosed, as it is the publication of the instant application.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



M. Henry Heines
Reg. No. 28,219

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
MHH:ath
60581748 v1



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/659,408	
			Filing Date	September 10, 2003	
			First Named Inventor	Parikh, Rajiv	
			Art Unit		
			Examiner Name		
Sheet	1	of	1	Attorney Docket Number	021956-000500US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	Letter from Douglas SWARTZ of Sheridan Ross to Daniel P Maguire of Maguire Law Office forwarding references and discussing each reference	
	AB	KHARITONOV, S.A. and P.J. Barnes; "Nitric oxide in exhaled air is a new marker of airway inflammation"; <u>Monaldi Arch Chest Dis.</u> ; December 1996; pp. 533-537; Vol. 51, No. 6. [Exhibit B]	
	AC	KHARITONOV, S.A. <i>et al.</i> ; "Increased nitric oxide in exhaled air of asthmatic patients"; <u>The Lancet</u> ; January 15, 1994; pp. 133-135; Vol. 343. [Exhibit C]	
	AD	COVAR, Ronina A. <i>et al.</i> ; "Relations between exhaled nitric oxide and measure of disease activity among children with mild-to-moderate asthma"; <u>J. Pediatr.</u> ; 2003; pp. 469-475; Vol. 142. [Exhibit D]	
	AE	JONES, S.L. <i>et al.</i> ; "Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose-response relationship"; <u>Eur. Respir. J.</u> ; 2002; 601-608; Vol. 20. [Exhibit E]	
	AF	SIPPEL, Jeffrey M. <i>et al.</i> ; "Exhaled nitric oxide levels correlate with measures of disease control in asthma"; <u>J. Allergy Clin. Immunol.</u> ; 2000; 645-650; Vol. 106. [Exhibit F]	
	AG	BECK-RIPP, J. <i>et al.</i> ; "Changes of exhaled nitric oxide during steroid treatment of childhood asthma"; <u>Eur. Respir. J.</u> ; 2002; 1015-1019; Vol. 19. [Exhibit G]	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.